双环醇治疗慢性乙型肝炎患者52例  

Clinical observations of bicyclol for the treatment of chronic hepatitis B

作　　者：王志明[1] 陈伟华[1] 刘丽宁[1] 李明山[1] 田琦琦[1] 

机构地区：[1]石家庄白求恩军医学院附属260医院,石家庄050041

出　　处：《中国新药杂志》2005年第7期917-918,共2页Chinese Journal of New Drugs

摘　　要：目的:对比双环醇及拉米夫定治疗慢性乙型肝炎的疗效。方法:慢性乙型肝炎患者随机分成双环醇组(52例)和拉米夫定组(30例),分别服用双环醇25mg,tid或拉米夫定100mg,qd,共24周。结果:治疗结束时,e抗原转阴率两组分别为7·4%与8·8%(P>0·05),总有效率两组分别为83·3%及67·3%(P>0·05)。HBVDNA阳性但e抗原阴性或ALT正常的患者亦适合双环醇治疗。疗前病毒定量的高低、性别及年龄并不影响疗效。结论:双环醇对乙型肝炎患者降低转氨酶及抗病毒疗效与拉米夫定类似,无明显不良反应。Objective：To evaluate the clinical effects of bicyclol versus lamivudine for the treatment of chronic hepatitis B.Methods： 82 patients with chronic hepatitis B were randomized orally to receive either 25 mg of bicyelol （ n = 52, rid） or 100 mg of lamivudine （ n = 30, qd） for 24 weeks. Results：At the end of the therapy, the bicyclol patients had a HBeAg sero-negative rates of 7.4%, compared with 8.8% for the lamivudine patients （ P 〉 0.05） . The overall efficacy rate of bicyclol and lamivudine treatment was 83.3 % versus 67.3 % （ P 〉 0.05）. Patients with HBV DNA positive but HBeAg negative and/or normal ALT responded the bicyclol very well. None of factors including quantity of HBV DNA load before the treatment, sex or age of patients affected the efficacy of bicyclol. Conclusion： Bicyclol is therapeutic equivalent to lamivudine and has better safety profiles in the treatment of chronic hepatitis B.

关 键 词：双环醇 乙型肝炎 乙型肝炎病毒脱氧核糖核酸 治疗 

分 类 号：R978.7[医药卫生—药品] R969.4[医药卫生—药学]